Despite disappointing trial results on Friday, the CEO of Bristol-Myers remains optimistic.» Read More
Patrick Mahaffy, Clovis Oncology CEO, weighs in on drug prices, business development, and immunotherapy with CNBC's Meg Tirrell.
Michael Yee, RBC Capital Markets biotech analyst, gives perspective to Puma Biotech and other action in the pharmaceutical industry.
*Intel falls on Altera buy, weighs on Nasdaq, Dow and S&P. *Microsoft jumps on report of German startup buy. "We're seeing a lot of counter trends in the market," said Rick Fier, director of trading at Conifer Securities in New York.
The "Halftime Report" traders give their trades for the second half.
Pfizer's share of the market for certain cancer drugs has increased from 10 to 20 percent, Chairman and CEO Ian Read tells CNBC.
Merck's executive vice president Dr. Roger Perlmutter, discusses research on immunotherapy for certain colon cancers, and the players in the fight against cancer.
Pfizer CEO Ian Read, discusses the PALOMA-3 trial for its oncology treatment Ibrance to treat breast cancer, drug pricing and competition in the pharmaceutical industry.
Giovanni Caforio, Bristol-Myers Squibb CEO, joins CNBC's Meg Tirrell to discuss data in lung cancer and the importance of valuable medicines becoming available to patients.
CNBC's Meg Tirrell has the update on the latest development from this year's American Society of Clinical Oncology meeting.
CNBC's Meg Tirrell, and Pascal Soriot, AstraZeneca executive director & CEO, discuss the promising results in using immunotherapy to treat all kinds of cancers.
*Roche, AstraZeneca gain on positive updates. LONDON, June 1- European shares held steady at the start of the month on Monday, with a rally in some drug stocks on the back of positive company updates offset by lingering concerns over Greece's debt situation and weaker commodity stocks. Drugmakers Roche and AstraZeneca, up 2.2 percent and 1 percent respectively,...
CNBC's Meg Tirrell, and Daniel O'Day, Roche Pharmaceuticals COO, talk about the the encouraging results in treating lung cancer and using precision medicines to personalize treatment.
SHANGHAI, June 1- China stocks jumped nearly 5 percent on Monday, regaining most of the ground lost in Thursday's sell-off, as investors sitting on growing piles of cash took advantage of that tumble to swoop on shares as a chorus of official media commentary asserted the bull market is not over yet. "The pattern in a bull market is that immediately after a plunge,...
On Friday, a Korean man was confirmed as China's first case after traveling to the country via Hong Kong with Asiana Airlines Inc. None of 64 people quarantined after contact with the man tested positive, state media reported. In Hong Kong, 299 people died from SARS and tourism dropped almost 90 percent during the worst-hit months. Korean Air Lines Co Ltd closed...
SHANGHAI, June 1- China's key CSI300 index posted its biggest single-day rise in two and a half years, as investors sitting on growing piles of cash took advantage of last week's tumble to swoop on shares, emboldened by a chorus of official media commentary asserting the bull market is not over yet. The CSI300 index of the largest listed companies in Shanghai and...
SHANGHAI, June 1- China stocks rose sharply on Monday morning, as investors took a positive view on fresh official economic surveys and welcomed a chorus of domestic media commentary asserting the bull market has not yet ended. In Hong Kong, both the Hang Seng index and the Hong Kong China Enterprises Index were up 0.7 percent. Growth in China's giant factory...
Discussing expectations for clinical oncology conference ASCO, with Eric Schmidt, Cowen & Co. biotech analyst. He weighs in on data from Puma Biotech, AstraZeneca and Incyte.
ALBANY, N.Y.— A federal appeals court has ruled that drug manufacturer Actavis PLC's attempted switch of patented Alzheimer's medication, which halted distribution of the old drug before its patent expires this summer, violates U.S. antitrust law. He alleged antitrust and state law violations by Actavis in pushing about 500,000 patients to its new patented...
Lilly never stops innovating, says CNBC's Jim Cramer explaining why he is watching shares of the pharmaceutical giant.
CNBC's Meg Tirrell, provides a preview of this weekend's meeting of the American Society of Clinical Oncology and which big pharma companies investors need to watch come Monday.